Klinik und Poliklinik für Neurologie

Experimental and Translational Neurooncology

 

The goal of Experimental and Translational Neuorooncology is to convert experimental cues from basic science studies on patient brain tumor tissue and specimens to clinical application. This venture is developed between the University Clinic Bonn Departments of Neurosurgery , Neurology / Division of Clinical Neuroonclogy, the Clinical Cooperation Unit Neurooncology and the Lichtenberg program ?Stem Cell Pathologies? . First clinical trials are currently in preparation.

Core funding is provided by the Medical Faculty of the University Bonn / Stem Cell Pathologies (Björn Scheffler; 2013-2015).

Key Publications

Glas M, Coch C, Trageser D, Simon M, Koch P, Mertens J, Quandel T, Daßler J, Gorris R, Reinartz R, Wieland A, von Lehe M, Pusch A, Roy K, Schlee M, Neumann H, Fimmers R, Herrlinger U, Brüstle O, Hartmann G, Besch R, Scheffler B. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells; accepted for publication.

Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. Vemurafenib for leptomeningeal melanomatosis: activity beyond the barrier. J Clin Oncol; accepted for publication.

Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Scheffler B, Laterra J. C-Met Signaling Induces a Reprogramming Network and Supports the Glioblastoma Stem-Like Phenotype. Proc Natl Acd Sci USA 2011;108:9951-9956.

Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U, Group Of The German Cancer Society FT. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011;70:445-453.

Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, Garbe S, Steinfarz B, Pietsch T, Steindler DA, Schramm J, Herrlinger U, Brüstle O, Scheffler B. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol 2010;68:264-269.

Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27:1257-1261.